Estrella Immunopharma Inc

ESLAW | Healthcare | NASDAQ
$0.13
+0.02 (+22.64%)

Key Metrics

Market Cap
$4.78M
P/E Ratio
N/A
EPS
$0.00
Beta
N/A
Dividend Yield
N/A
ROE
167.91%
Current Ratio
0.24

Company Information

Industry
Biotechnology

About Estrella Immunopharma Inc

Estrella Immunopharma Inc a preclinicalstage biopharmaceutical company develops Tcell therapies for blood cancers and solid tumors in the United States The companys lead product candidates include EB103 for the treatment of diffuse large Bcell lymphoma and is in pre clinical trial and EB104 to treat diffuse large Bcell lymphoma and acute lymphocytic leukemia It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugenes product candidate CF33CD19t in conjunction with EB103 Estrella Immunopharma Inc is based in EmeryVille California

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2026-05-18 $-0.05 $-0.08 +-40.5%
2026-03-18 $-0.14 $-0.18 +-22.2%
2025-11-12 $-0.13 $-0.19 +-30.6%
2025-08-11 $-0.15 $-0.07 119.0%

Financial Ratios (TTM)

Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
0.00%
ROA
-362.33%
Price to Book
-8.95
Price to Sales
0.00